PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21865851-8	2011	Meanwhile, all the effects were abolished by specific beta(3)-AR antagonist, SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	77-85	adrenoceptor beta 3	Homo sapiens	54-64
20930473-8	2010	Intraperitoneal pre-treatment with SR 59230A partly inhibited the effects of BRL 37344 alone, indicating that the increase in levels of circulating ALT by BRL 37344 was attributable to a beta(3)-adrenoceptor-stimulating effect.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	35-44	glutamic pyruvic transaminase, soluble	Mus musculus	148-151
20930473-8	2010	Intraperitoneal pre-treatment with SR 59230A partly inhibited the effects of BRL 37344 alone, indicating that the increase in levels of circulating ALT by BRL 37344 was attributable to a beta(3)-adrenoceptor-stimulating effect.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	35-44	adrenergic receptor, beta 3	Mus musculus	187-207
20410872-9	2010	BRL potentiation of LPCS eIPSCs was blocked by the selective beta 3-AR antagonist, SR59230A, or by intracellular dialysis of Rp-CAMPS (cAMP-dependent protein kinase inhibitor), and this enhancement was not associated with any changes in spontaneous IPSCs or LPCS paired-pulse ratio.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	83-91	bromodomain containing 1	Homo sapiens	0-3
19619525-6	2009	The beta(3)-adrenoceptor antagonist SR59230A (1 microM) significantly inhibited the relaxing effects of CL316,243 on basal tone and neurogenic contractions (pA(2)=7.0 and 7.2, respectively).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	36-44	adrenergic receptor, beta 3	Mus musculus	4-24
20093127-5	2010	These relaxant responses were blocked by SR59230A, a selective beta(3)-antagonist but not by beta(1)/beta(2)-selective antagonists, neuronal inhibitor or inhibition of nitric oxide synthase.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	41-49	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	63-69
20654104-2	2010	METHODS: Seven weight-matched normal adult rats (control), 18 ISO induced heart failure rats and 21 ISO induced heart failure rats treated with specific beta(3)-AR inhibitor, SR59230A for 6 weeks were included in this study.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	175-183	adrenoceptor beta 3	Rattus norvegicus	153-163
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	182-190	cell death-inducing DFFA-like effector a	Rattus norvegicus	37-42
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	182-190	uncoupling protein 1	Rattus norvegicus	47-51
19577538-6	2009	The cold exposure-induced changes of CIDEA and UCP1 were attenuated by intraperitoneal pretreatment with propranolol (a non-selective beta-adrenoreceptor antagonist) (2mg/animal) or SR59230A (a selective beta(3)-adrenoreceptor antagonist) (2mg/animal), respectively.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	182-190	adrenoceptor beta 3	Rattus norvegicus	204-226
18799656-3	2008	SR59230A, a specific beta3-AR antagonist, and H89, a PKA inhibitor, reduced the inhibitory effect of BRL 37344.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	0-8	adrenoceptor beta 3	Rattus norvegicus	21-29
19491297-0	2009	Reversal of high pancreatic islet and white adipose tissue blood flow in type 2 diabetic GK rats by administration of the beta3-adrenoceptor inhibitor SR-59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	151-160	adrenoceptor beta 3	Rattus norvegicus	122-140
19491297-2	2009	The aim of the study was to examine if these increased blood flow values in GK rats could be affected by the beta(3)-adrenoceptor antagonist SR-59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	141-150	adrenoceptor beta 3	Rattus norvegicus	109-129
17669397-12	2007	pretreatment with the selective beta(3) adrenoceptor antagonist SR59230A (5 mg/kg) blocked the effects of SR58611A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	64-72	adrenoceptor beta 3	Rattus norvegicus	32-52
18455721-12	2008	In NOS-3-KO mice, BRL 37344 produced concentration-dependent relaxations which were abolished by SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	97-105	nitric oxide synthase 3, endothelial cell	Mus musculus	3-8
17717109-0	2007	Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	150-158	adrenergic receptor, beta 3	Mus musculus	33-51
17717109-6	2007	Examination of the pathways stimulated by (-)-isoproterenol, CL316243, and SR59230A for both ECAR and cAMP accumulation suggested that the cAMP pathway predominates in CHObeta(3)H cells, whereas p38 MAPK is a major contributor to ECAR in CHObeta(3)L cells and was the sole contributor to responses to SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	75-83	mitogen-activated protein kinase 14	Mus musculus	195-198
17717109-6	2007	Examination of the pathways stimulated by (-)-isoproterenol, CL316243, and SR59230A for both ECAR and cAMP accumulation suggested that the cAMP pathway predominates in CHObeta(3)H cells, whereas p38 MAPK is a major contributor to ECAR in CHObeta(3)L cells and was the sole contributor to responses to SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	75-83	mitogen-activated protein kinase 1	Mus musculus	199-203
17996136-1	2007	OBJECTIVE: To investigate the effect of beta(3)-adrenoceptor (beta(3)-AR) antagonist (SR59230A) on the cardiac function and left ventricular remodeling in a rat model of heart failure induced by isoproterenol (ISO), and to probe into its mechanism.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	86-94	adrenoceptor beta 3	Rattus norvegicus	40-60
17996136-1	2007	OBJECTIVE: To investigate the effect of beta(3)-adrenoceptor (beta(3)-AR) antagonist (SR59230A) on the cardiac function and left ventricular remodeling in a rat model of heart failure induced by isoproterenol (ISO), and to probe into its mechanism.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	86-94	adrenoceptor beta 3	Rattus norvegicus	62-72
17996136-10	2007	CONCLUSION: beta(3)-AR antagonist SR59230A can block the beta(3)-AR-NOS-cGMP pathway and improve cardiac function in heart failure in rat when if is administered for a long term.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	34-42	adrenoceptor beta 3	Rattus norvegicus	12-22
17996136-10	2007	CONCLUSION: beta(3)-AR antagonist SR59230A can block the beta(3)-AR-NOS-cGMP pathway and improve cardiac function in heart failure in rat when if is administered for a long term.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	34-42	adrenoceptor beta 3	Rattus norvegicus	57-67
16899794-8	2006	Administration of alpha-methyl-p-tyrosine or a combination of SR59230A and propranolol reversed the cold-exposure-induced decreases in serum adiponectin concentrations and adiponectin mRNA expression in these tissues.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	62-70	adiponectin, C1Q and collagen domain containing	Mus musculus	141-152
17280840-9	2007	The effects of dl-nebivolol on intracellular formation of NO, eNOS activity and intracellular Ca(2+) were partially antagonized by the antagonists of beta(1-2)-AR nadolol or by the beta(3)-AR antagonist SR59230A and further antagonized by their combination or by (beta(1-2-3)-AR antagonist bupranolol.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	203-211	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	150-158
17280840-9	2007	The effects of dl-nebivolol on intracellular formation of NO, eNOS activity and intracellular Ca(2+) were partially antagonized by the antagonists of beta(1-2)-AR nadolol or by the beta(3)-AR antagonist SR59230A and further antagonized by their combination or by (beta(1-2-3)-AR antagonist bupranolol.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	203-211	adrenoceptor beta 3	Homo sapiens	181-191
16899794-8	2006	Administration of alpha-methyl-p-tyrosine or a combination of SR59230A and propranolol reversed the cold-exposure-induced decreases in serum adiponectin concentrations and adiponectin mRNA expression in these tissues.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	62-70	adiponectin, C1Q and collagen domain containing	Mus musculus	172-183
16091956-5	2006	The anti-proteolytic effect of CL or epinephrine was partially prevented by 10(-5) M SR 59230A, a selective beta3-adrenoceptor antagonist.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	85-94	adrenoceptor beta 3	Rattus norvegicus	108-126
16399693-7	2006	Importantly, the beta3-specific antagonist SR 59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate] severely blunted fasting-induced torpor in control mice, whereas other AR antagonists were ineffective.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	43-52	adrenergic receptor, beta 3	Mus musculus	211-213
15574684-0	2005	Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate].	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	79-87	adrenergic receptor, beta 3	Mus musculus	48-66
16014404-12	2005	This effect was completely blocked after preincubation of the cells with 1 microM bupranolol, a nonspecific beta-adrenoreceptor blocker, or 100 nM SR59230a, a specific beta3-adrenoreceptor antagonist.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	147-155	adrenoceptor beta 3	Homo sapiens	168-188
15574684-11	2005	Therefore, SR59230A displays agonist and antagonist actions at the mouse beta(3)-adrenoceptor.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	11-19	adrenergic receptor, beta 3	Mus musculus	73-93
15246563-3	2004	ZAG induced a concentration-dependent increase in the expression of UCP-1 in primary cultures of brown, but not white, adipose tissue, and this effect was attenuated by the beta3-adrenergic receptor (beta3-AR) antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	221-229	alpha-2-glycoprotein 1, zinc	Mus musculus	0-3
16301818-9	2005	All these effects were blocked by the beta3 adrenoceptor antagonist (SR 59230A).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	69-78	adrenoceptor beta 3	Homo sapiens	38-56
15246563-3	2004	ZAG induced a concentration-dependent increase in the expression of UCP-1 in primary cultures of brown, but not white, adipose tissue, and this effect was attenuated by the beta3-adrenergic receptor (beta3-AR) antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	221-229	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	68-73
15246563-3	2004	ZAG induced a concentration-dependent increase in the expression of UCP-1 in primary cultures of brown, but not white, adipose tissue, and this effect was attenuated by the beta3-adrenergic receptor (beta3-AR) antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	221-229	adrenergic receptor, beta 3	Mus musculus	173-198
15246563-3	2004	ZAG induced a concentration-dependent increase in the expression of UCP-1 in primary cultures of brown, but not white, adipose tissue, and this effect was attenuated by the beta3-adrenergic receptor (beta3-AR) antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	221-229	adrenergic receptor, beta 3	Mus musculus	200-208
15026812-5	2004	This effect was attenuated by the beta3 antagonist SR59230A, suggesting that it was mediated through a beta3 adrenoreceptor.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	51-59	histocompatibility 2, P region beta locus	Mus musculus	101-108
14984739-4	2004	The effect was enhanced by the cyclic AMP phosphodiesterase inhibitor Ro20-1724, and attenuated by freeze/thawing and the specific beta3-adrenoreceptor antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	163-171	adrenoceptor beta 3	Homo sapiens	131-151
11159692-4	2001	In KO and FVB mice, SR59230A (100 nM) (beta(3)-AR antagonist) antagonized responses to (-)-isoprenaline in both KO and FVB mice.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	20-28	adrenergic receptor, beta 3	Mus musculus	39-49
12490598-9	2003	plus SR59230A [a selective beta3-adrenoceptor antagonist; (3-(2-ethylphenoxy)-1(1S)-1,2,3,4-tetrahydronaphth-1-ylaminol-(2S)2-propanol oxalate); 1 mg/kg, i.v.].	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	5-13	adrenoceptor beta 3	Canis lupus familiaris	27-45
11475797-5	2001	In both functional and biochemical studies, SR 59119A was only antagonized by the beta 3-adrenoceptor antagonist SR 59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	113-122	adrenoceptor beta 3	Homo sapiens	82-101
11282126-2	2001	In the present study, we have shown that SR59230A (3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate), a selective beta(3)-adrenoceptor antagonist, possesses agonistic activities at atypical beta-adrenoceptors in these tissues.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	41-49	beta-3 adrenergic receptor	Cavia porcellus	152-172
11275008-3	2001	Responses to isoprenaline were reduced in tissues from hypothyroid rats, as was the shift produced with the beta(3)-adrenoceptor antagonist, 3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate (SR 59230A).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	229-238	adrenoceptor beta 3	Rattus norvegicus	108-128
11875710-3	2002	In both cases cyclic AMP production was attenuated by SR59230A confirming that the effect is mediated through a beta3-adrenoceptor.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	54-62	adrenoceptor beta 3	Homo sapiens	112-130
11159692-8	2001	Responses to CL316243 (beta(3)-AR agonist) in ileum from FVB mice were antagonized by SR59230A (100 nM) but not by propranolol (1 microM) or carvedilol (100 nM).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	86-94	adrenergic receptor, beta 3	Mus musculus	23-33
9726658-7	1998	The curves obtained in the presence of antagonists suggested an action mediated by beta3-adrenoceptor stimulation, since propranolol did not antagonize the action of SR 59119A and SR 59104A, whereas the combination of propranolol and SR 59230A significantly displaced the concentration-response curve of these agonists to the right.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	234-243	adrenoceptor beta 3	Homo sapiens	83-101
10725275-8	2000	SR59230A treatment markedly increased beta(3)-AR mRN levels in ileum and BAT but not in WAT.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	0-8	adrenergic receptor, beta 3	Mus musculus	38-48
10963888-7	2000	Pre-treatment with the selective beta(3)-AR antagonist SR59230A resulted in a significant decrease in the number of Fos positive cells in all those areas compared with rats treated with CL316243 alone.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	55-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	116-119
10864880-1	2000	The smooth muscle relaxant responses to the mixed beta(3)-, putative beta(4)-adrenoceptor agonist, (-)-CGP 12177 in rat colon are partially resistant to blockade by the beta(3)-adrenoceptor antagonist SR59230A suggesting involvement of beta(3)- and putative beta(4)-adrenoceptors.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	201-209	adrenoceptor beta 3	Rattus norvegicus	169-189
10742307-5	2000	Application of both propranolol (a non-selective beta(1)- and beta(2)-adrenoceptor antagonist) and SR59230A (a beta(3)-adrenoceptor antagonist) were needed to inhibit the isoprenaline-induced increase in L-type Ca(2+) channel current.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	99-107	adrenoceptor beta 3	Rattus norvegicus	111-131
10226761-12	1999	SR 58611 A (200 nmol kg-1) was reduced by pretreatment with beta-adrenoceptor antagonists [propranolol, nadolol, bupranolol or the beta3-adrenoceptor selective antagonist, SR 59230 A (2 mg kg-1 i.v.)]	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	172-182	adrenoceptor beta 3	Canis lupus familiaris	131-149
9718277-0	1998	SR59230A blocks beta3-adrenoceptor-linked modulation of upcoupling protein-1 and leptin in rat brown adipocytes.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	0-8	adrenoceptor beta 3	Rattus norvegicus	16-34
9718277-0	1998	SR59230A blocks beta3-adrenoceptor-linked modulation of upcoupling protein-1 and leptin in rat brown adipocytes.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	0-8	leptin	Rattus norvegicus	81-87
34646131-6	2021	In addition to reduce tumor growth, both propranolol and SR59230A, beta1-/beta2-and beta3-AR antagonists, respectively, attenuated mechanical allodynia, the number of macrophages and an oxidative stress by-product accumulated in the ipsilateral tibial nerve.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	57-65	ferredoxin reductase	Mus musculus	90-92
34846398-8	2021	The thermogenic effect of ZEA was abolished by beta3-AR antagonist (SR59230A) treatment.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	68-76	adenosine A3 receptor	Mus musculus	47-55
34676684-6	2021	We find that administration of the selective beta3-AR antagonist SR59230A to an ADPKD mouse model (Pkd1fl/fl ;Pax8rtTA ;TetO-Cre) decreases cAMP levels, producing a significant reduction in kidney/body weight ratio and a partial improvement in kidney function.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	65-73	adenosine A3 receptor	Mus musculus	45-53
8730727-0	1996	Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	124-133	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	32-38
8730727-0	1996	Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	124-133	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	82-88
8730727-5	1996	Although only one of these beta 3-selective agonists was effective, the remarkably high potency of SR 59230A as a stereospecific antagonist of non-beta 1 non-beta 2 relaxation of human colonic muscle by isoprenaline provides strong functional evidence of beta 3-adrenoceptors in that tissue.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	99-108	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	158-164
8730727-5	1996	Although only one of these beta 3-selective agonists was effective, the remarkably high potency of SR 59230A as a stereospecific antagonist of non-beta 1 non-beta 2 relaxation of human colonic muscle by isoprenaline provides strong functional evidence of beta 3-adrenoceptors in that tissue.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	99-108	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	255-261
33799536-10	2021	beta3-ARs play a major role in regulating stromal cell differentiation, and the antagonist SR59230A promotes differentiation of different progenitor cells in hematopoietic tumors, suggesting that beta3-ARs agonism and antagonism could be exploited for clinical benefit.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	91-99	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	196-201
35589963-6	2022	Mechanistically, deficiency of TRPC5 in the CeA boosted nonshivering thermogenesis under cold stimulation by stimulating sympathetic nerves, as the beta3-adrenoceptor (Adrb3) antagonist SR59230A blocked the effect of TRPC5 KO on this process.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	186-194	transient receptor potential cation channel, subfamily C, member 5	Mus musculus	31-36
35589963-6	2022	Mechanistically, deficiency of TRPC5 in the CeA boosted nonshivering thermogenesis under cold stimulation by stimulating sympathetic nerves, as the beta3-adrenoceptor (Adrb3) antagonist SR59230A blocked the effect of TRPC5 KO on this process.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	186-194	adrenergic receptor, beta 3	Mus musculus	148-166
35589963-6	2022	Mechanistically, deficiency of TRPC5 in the CeA boosted nonshivering thermogenesis under cold stimulation by stimulating sympathetic nerves, as the beta3-adrenoceptor (Adrb3) antagonist SR59230A blocked the effect of TRPC5 KO on this process.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	186-194	adrenergic receptor, beta 3	Mus musculus	168-173
35589963-6	2022	Mechanistically, deficiency of TRPC5 in the CeA boosted nonshivering thermogenesis under cold stimulation by stimulating sympathetic nerves, as the beta3-adrenoceptor (Adrb3) antagonist SR59230A blocked the effect of TRPC5 KO on this process.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	186-194	transient receptor potential cation channel, subfamily C, member 5	Mus musculus	217-222
32954502-7	2021	The neuroprotective effect of noradrenaline was inhibited by SR59230A, a selective beta3 -adrenoceptor antagonist, and CL316243, a selective beta3 -adrenoceptor agonist, mimicked the neuroprotective effect of noradrenaline.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	61-69	adrenoceptor beta 3	Homo sapiens	83-102
33174240-4	2020	We found that blockade of beta3-ARs by SR 59230A impaired the acquisition of the rotarod task with no effect on general locomotion.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	39-48	olfactory receptor family 2 subfamily B member 4	Mus musculus	26-31
33297453-6	2020	Furthermore, newborn mice were treated straight after birth with BRL37344, a beta3-AR agonist, and sacrificed after 7 h. SR59230A, at the doses demonstrated effective in reducing cancer progression (10 and 20 mg/kg) in acute and chronic mode, did not induce fetal DA constriction and did not impair the DA ability to close after birth, whereas at the highest dose (40 mg/kg), it was shown to cause DA constriction and preterm-delivery.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	121-129	olfactory receptor family 2 subfamily B member 4	Mus musculus	77-82
32034680-7	2020	Chromium-induced myometrial relaxation was also significantly (P < 0.05) reduced in the presence of ICI 118,551 (a selective beta2-antagonist) and SR 59230A (a selective beta3-antagonist).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	150-159	UDP glucuronosyltransferase family 1 member A8	Rattus norvegicus	173-178
31853320-0	2020	beta3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline-induced pulmonary arterial hypertension.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	37-45	adrenoceptor beta 3	Rattus norvegicus	0-25
32545695-3	2020	Here, we evaluated beta3-AR in myeloid leukemia cell lines and the effect of beta3-AR antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	97-105	adenosine A3 receptor	Homo sapiens	77-85
32545695-5	2020	Using flow cytometry, we assessed cell death in different in vitro myeloid leukemia cell lines (K562, KCL22, HEL, HL60) treated with SR59230A in hypoxia and normoxia; furthermore, we analyzed beta3-AR expression.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	133-141	adenosine A3 receptor	Homo sapiens	192-200
32545695-9	2020	Finally, we observed that SR59230A plus doxorubicin increased doxorubicin resistance reversion mainly in hypoxia, probably acting on P-gp.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	26-34	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
31853320-4	2020	The present study aimed to investigate the functional involvement of beta3-AR and the effects of the beta3-AR antagonist, SR59230A, in PAH and subsequent heart failure.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	122-130	adrenoceptor beta 3	Rattus norvegicus	101-109
31853320-7	2020	Additionally, the expression level of beta3-AR was significantly upregulated in the lung and heart tissues of PAH rats compared with the sham group (P<0.01), and SR59230A treatment inhibited this increase in the lung (P<0.05), but not the heart.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	165-173	adrenoceptor beta 3	Rattus norvegicus	38-46
31853320-10	2020	Furthermore, blocking beta3-AR with SR59230A may alleviate the structural changes and inflammatory infiltration to the lung as a result of reduced oxidative stress.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	36-44	adrenoceptor beta 3	Rattus norvegicus	22-30
31030945-6	2019	The mechanistic study revealed that beta3-AR knockdown and SR59230A inhibited the phosphorylation and thereby the activation of the mTOR/p70S6K pathway.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	59-67	mechanistic target of rapamycin kinase	Homo sapiens	132-136
31030945-6	2019	The mechanistic study revealed that beta3-AR knockdown and SR59230A inhibited the phosphorylation and thereby the activation of the mTOR/p70S6K pathway.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	59-67	ribosomal protein S6 kinase B1	Homo sapiens	137-143
31030945-7	2019	Activation of the mTOR pathway with the activator MHY1485 reversed the inhibitory effect of SR59230A on NB cell growth.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	92-100	mechanistic target of rapamycin kinase	Homo sapiens	18-22
28843854-7	2017	Pretreatment with the beta3 blocker, SR59230A, and the cyclooxygenase blocker, indomethacin, inhibited the NURP33- or NMU-induced increase of BS-T.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	37-45	neuromedin U	Rattus norvegicus	118-121
31061315-9	2019	In the presence of propranolol (10-6 M), noradrenaline-induced relaxation was competitively inhibited by bupranolol (3 x 10-7-3 x 10-6 M) or SR59230A (10-7-10-6 M; selective beta3-adrenoceptor antagonist), with their pA2 values calculated to be 6.64 and 7.27, respectively.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	141-149	adrenoceptor beta 3	Rattus norvegicus	174-192
30538804-9	2018	These effects are reverted by SR59230A, the specific beta3-AR antagonist, causing an increase in mtROS.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	30-38	adrenoceptor beta 3	Homo sapiens	53-61
30126894-9	2018	Importantly, all of these effects were abolished upon treatment with the beta3-adrenoceptor antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	103-111	adrenergic receptor, beta 3	Mus musculus	73-91
30959019-12	2019	infusion of the beta3-adrenergic receptor antagonist SR59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	53-61	adrenoceptor beta 3	Rattus norvegicus	16-41
31052299-8	2019	Since ES cells are susceptible to an increased oxidative stress to reduce cell viability, here we demonstrate that administration of beta3-ARs antagonist, SR59230A, improves the apigenin effect on cell death, identifying beta3-AR as a potential discriminating factor that could address the use of apigenin in ES.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	155-163	adrenoceptor beta 3	Homo sapiens	133-141
29579398-8	2018	beta3-AR antagonist SR 59230A and mTORC1 inhibitor rapamycin blocked Rgc32-/--induced thermogenic gene expression in both iWAT and interscapular BAT.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	20-29	adrenoceptor beta 3	Homo sapiens	0-8
29579398-8	2018	beta3-AR antagonist SR 59230A and mTORC1 inhibitor rapamycin blocked Rgc32-/--induced thermogenic gene expression in both iWAT and interscapular BAT.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	20-29	regulator of cell cycle	Homo sapiens	69-74
28622359-5	2017	Animals were treated with either moderate aerobic exercise by swimming for 9 weeks and/or the beta3-AR-specific inhibitor SR59230A at 0.1 mg/kg/hour one day after TAC operation.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	122-130	adrenergic receptor, beta 3	Mus musculus	94-102
28622359-12	2017	However, selective inhibition of beta3-AR by SR59230A abolished the upregulation and activation of nNOS induced NO production.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	45-53	adrenergic receptor, beta 3	Mus musculus	33-41
28622359-12	2017	However, selective inhibition of beta3-AR by SR59230A abolished the upregulation and activation of nNOS induced NO production.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	45-53	nitric oxide synthase 1, neuronal	Mus musculus	99-103
27437788-5	2016	Exposure to a cold swim or injection of BRL37344 (beta3 adrenergic agonist) each enhanced musculoskeletal hyperalgesia, as indicated by morphine-sensitive decreases in grip force responses, whereas SR59230A (beta3 adrenergic antagonist) attenuated swim-induced hyperalgesia.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	198-206	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	50-55
28389717-5	2017	Selective blockade of beta1 (CGP20712) or beta3 (SR59230A), but not beta2 (ICI118,551) adrenoceptors, greatly increased alpha-adrenergic constriction (norepinephrine) of aorta in female SHRs, but not in male SHRs at 12 weeks of age.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	49-57	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	42-47
28394360-7	2017	Finally, pharmacological blockage of sympathetic activity on adipose tissue using the beta3-adrenergic receptor antagonist, SR59230a, suppressed loss of visceral adipose mass in response to diet.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	124-132	adrenergic receptor, beta 3	Mus musculus	86-111
27437788-5	2016	Exposure to a cold swim or injection of BRL37344 (beta3 adrenergic agonist) each enhanced musculoskeletal hyperalgesia, as indicated by morphine-sensitive decreases in grip force responses, whereas SR59230A (beta3 adrenergic antagonist) attenuated swim-induced hyperalgesia.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	198-206	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	208-213
24256707-7	2014	Nebivolol-mediated lipolysis was blocked by SR59230A, a specific beta3AR antagonist, suggesting that nebivolol acts through beta3AR in human adipocytes.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	44-52	adrenoceptor beta 3	Homo sapiens	65-72
26724392-6	2016	This increase was inhibited by a non-selective beta-adrenoceptor antagonist propranolol and by a selective beta3-adrenoceptor antagonist SR59230A, but not by a non-selective alpha-adrenoceptor antagonist phenoxybenzamine, or by a selective beta1-adrenoceptor antagonist atenolol or by a selective beta2-adrenoceptor antagonist butoxamine.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	137-145	adrenoceptor beta 3	Homo sapiens	107-125
26724392-6	2016	This increase was inhibited by a non-selective beta-adrenoceptor antagonist propranolol and by a selective beta3-adrenoceptor antagonist SR59230A, but not by a non-selective alpha-adrenoceptor antagonist phenoxybenzamine, or by a selective beta1-adrenoceptor antagonist atenolol or by a selective beta2-adrenoceptor antagonist butoxamine.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	137-145	adrenoceptor beta 1	Homo sapiens	240-258
26724392-6	2016	This increase was inhibited by a non-selective beta-adrenoceptor antagonist propranolol and by a selective beta3-adrenoceptor antagonist SR59230A, but not by a non-selective alpha-adrenoceptor antagonist phenoxybenzamine, or by a selective beta1-adrenoceptor antagonist atenolol or by a selective beta2-adrenoceptor antagonist butoxamine.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	137-145	adrenoceptor beta 2	Homo sapiens	297-315
25725113-5	2015	beta3-adrenoceptor antagonists SR59230A and L748337 blocked the inhibitory effects of BRL37344.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	31-39	adrenergic receptor, beta 3	Mus musculus	0-18
25566095-7	2014	beta3-adrenoceptor antagonist (SR59230A) reduced tyramine-stimulated norepinephrine release in both strains and the secretion of epinephrine in hypertensive rats.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	31-39	adrenoceptor beta 3	Rattus norvegicus	0-18
26910302-4	2016	Inhibition of ADRB3 with selective antagonist SR59230A caused serious vascular injury in vivo, even though UCP1 expression was downregulated.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	46-54	adrenergic receptor, beta 3	Mus musculus	14-19
24911015-5	2014	Animals were administrated with beta3-AR agonist BRL37344 (BRL) or beta3-AR inhibitor SR59230A (SR) respectively at 0.1 mg/kg/hour one day after MI operation.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	86-88	adrenoceptor beta 3	Homo sapiens	67-75
24256707-7	2014	Nebivolol-mediated lipolysis was blocked by SR59230A, a specific beta3AR antagonist, suggesting that nebivolol acts through beta3AR in human adipocytes.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	44-52	adrenoceptor beta 3	Homo sapiens	124-131
22749993-0	2012	Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	77-86	potassium inwardly rectifying channel subfamily J member 2 L homeolog	Xenopus laevis	22-28
24144049-11	2013	The vasorelaxations induced by SR 58611A and celiprolol were inhibited in the presence of SR 59230A and L-748337 (2 selective beta(3)-adrenoceptor antagonists).	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	90-99	adrenoceptor beta 3	Homo sapiens	126-146
22564532-0	2012	Two-week treatment with the beta3-adrenoceptor antagonist SR59230A normalizes the increased pancreatic islet blood flow in type 2 diabetic GK rats.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	58-66	adrenoceptor beta 3	Rattus norvegicus	28-46
22749993-6	2012	SR59230A inhibited homomeric Kir2.1 channels with an IC(50) of 33muM.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	0-8	potassium inwardly rectifying channel subfamily J member 2 L homeolog	Xenopus laevis	29-35
22749993-7	2012	Homomeric Kir2.2 and Kir2.3 channels and Kir2.x heteromers were also inhibited by SR59230A with similar potency.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	82-90	potassium inwardly rectifying channel subfamily J member 4 S homeolog	Xenopus laevis	21-27
22749993-10	2012	These findings establish SR59230A as a novel inhibitor of Kir2.1-2.3 channels with a favorable profile with respect to additional effects on other cardiac repolarizing potassium channels.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	25-33	potassium inwardly rectifying channel subfamily J member 2 L homeolog	Xenopus laevis	58-64
22197203-7	2012	The selective beta(3)-AR antagonist SR59230A shifted the concentration-response curve in a concentration-dependent manner to TRK-380 for the resting tension of human detrusor strips to the right.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	36-44	adrenoceptor beta 3	Homo sapiens	14-24
22197203-7	2012	The selective beta(3)-AR antagonist SR59230A shifted the concentration-response curve in a concentration-dependent manner to TRK-380 for the resting tension of human detrusor strips to the right.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	36-44	neurotrophic receptor tyrosine kinase 1	Homo sapiens	125-128
22442641-0	2012	beta(3)-Adrenoceptor Antagonist SR59230A Attenuates the Imbalance of Systemic and Myocardial Oxygen Transport Induced by Dopamine in Newborn Lambs.	3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate	32-40	beta-3 adrenergic receptor	Ovis aries	0-20